1116 - Combination of the indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i) BMS-986205 with nivolumab (nivo): Updated safety across all tumors and efficacy in advanced bladder cancer (advBC) by patient (pt) subgroup. - Moreno, V.; Luke, J.; Gelmon, K.; Joshua, A.M.; Varga, A.I.; Desai, J.; Markman, B.; Gomez-Roca, C.A.; De Braud, F.; Patel, S.P.; Carlino, M.S.; Siu, L.L.; et al. (European Urology Supplements, 2019)